Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression

Pharmacological Research

Volumn 111, Issue , 2016, Pages 688-702

  Patil, Naeem K ^a   Bohannon, Julia K ^a   Sherwood, Edward R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti PD 1; Anti PD L1; Biomarkers; Flt3 ligand; IFN ; Immunosuppression; Immunotherapy; Interleukin 15; Interleukin 7; Sepsis; T cell

Indexed keywords

BIOLOGICAL MARKER; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FLT3 LIGAND; INTERLEUKIN 15; PHOSPHORYL LIPID A; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN ANTIBODY; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; APOPTOSIS; CELL DAMAGE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION RESISTANCE; LYMPHOCYTE FUNCTION; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; T LYMPHOCYTE; ANIMAL; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; BIOMARKERS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SEPSIS; T-LYMPHOCYTES;

EID: 84979896363     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.019     Document Type: Review

References (169)

1. [1] Mayr, F.B., Yende, S., Angus, D.C., Epidemiology of severe sepsis. Virulence 5:1 (2014), 4–11.
2. [2] Bone, R.C., Sibbald, W.J., Sprung, C.L., The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:6 (1992), 1481–1483.
3. [3] Fleischmann, C., Scherag, A., Adhikari, N.K., Hartog, C.S., Tsaganos, T., Schlattmann, P., Angus, D.C., Reinhart, K.T., International Forum of Acute Care, Assessment of global incidence and mortality of hospital-treated sepsis. Am. J. Respir. Crit. Care Med. 193:3 (2016), 259–272.
4. [4] Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M., Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., van der Poll, T., Vincent, J.L., Angus, D.C., The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:8 (2016), 801–810.
5. [5] Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:7 (2001), 1303–1310.
6. [6] Martin, G.S., Mannino, D.M., Moss, M., The effect of age on the development and outcome of adult sepsis. Crit. Care Med. 34:1 (2006), 15–21.
7. [7] Hotchkiss, R.S., Karl, I.E., The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:2 (2003), 138–150.
8. [8] Cohen, J., Opal, S., Calandra, T., Sepsis studies need new direction. Lancet Infect. Dis. 12:7 (2012), 503–505.
9. [9] Angus, D.C., The search for effective therapy for sepsis: back to the drawing board?. JAMA 306:23 (2011), 2614–2615.
10. [10] Abraham, E., Glauser, M.P., Butler, T., Garbino, J., Gelmont, D., Laterre, P.F., Kudsk, K., Bruining, H.A., Otto, C., Tobin, E., Zwingelstein, C., Lesslauer, W., Leighton, A., p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277:19 (1997), 1531–1538.
11. [11] Hotchkiss, R.S., Opal, S., Immunotherapy for sepsis—a new approach against an ancient foe. N. Engl. J. Med. 363:1 (2010), 87–89.
12. [12] Schorr, C.A., Dellinger, R.P., The surviving sepsis campaign: past, present and future. Trends Mol. Med. 20:4 (2014), 192–194.
13. [13] Gaieski, D.F., Edwards, J.M., Kallan, M.J., Carr, B.G., Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41:5 (2013), 1167–1174.
14. [14] Hotchkiss, R.S., Coopersmith, C.M., McDunn, J.E., Ferguson, T.A., The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15:5 (2009), 496–497.
15. [15] Delano, M.J., Ward, P.A., Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. J. Clin. Invest. 126:1 (2016), 23–31.
16. [16] Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13:3 (2013), 260–268.
17. [17] Boomer, J.S., Green, J.M., Hotchkiss, R.S., The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. Virulence 5:1 (2014), 45–56.
18. [18] Tang, B.M., Huang, S.J., McLean, A.S., Genome-wide transcription profiling of human sepsis: a systematic review. Crit. Care, 14(6), 2010, R237.
19. [19] Monneret, G., Venet, F., Kullberg, B.J., Netea, M.G., ICU-acquired immunosuppression and the risk for secondary fungal infections. Med. Mycol. 49:Suppl. 1 (2011), S17–23.
20. [20] Otto, G.P., Sossdorf, M., Claus, R.A., Rodel, J., Menge, K., Reinhart, K., Bauer, M., Riedemann, N.C., The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care, 15(4), 2011, R183.
21. [21] Boomer, J.S., To, K., Chang, K.C., Takasu, O., Osborne, D.F., Walton, A.H., Bricker, T.L., Jarman, S.D. 2nd, Kreisel, D., Krupnick, A.S., Srivastava, A., Swanson, P.E., Green, J.M., Hotchkiss, R.S., Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306:23 (2011), 2594–2605.
22. [22] Unsinger, J., Burnham, C.A., McDonough, J., Morre, M., Prakash, P.S., Caldwell, C.C., Hotchkiss, W.M. Jr., Dunne, R.S., Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J. Infect. Dis. 206:4 (2012), 606–616.
23. [23] Unsinger, J., McGlynn, M., Kasten, K.R., Hoekzema, A.S., Watanabe, E., Muenzer, J.T., McDonough, J.S., Tschoep, J., Ferguson, T.A., McDunn, J.E., Morre, M., Hildeman, D.A., Caldwell, C.C., Hotchkiss, R.S., IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184:7 (2010), 3768–3779.
24. [24] Hotchkiss, R.S., Chang, K.C., Swanson, P.E., Tinsley, K.W., Hui, J.J., Klender, P., Xanthoudakis, S., Roy, S., Black, C., Grimm, E., Aspiotis, R., Han, Y., Nicholson, D.W., Karl, I.E., Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1:6 (2000), 496–501.
25. [25] Williams, M.A., Bevan, M.J., Effector and memory CTL differentiation. Annu. Rev. Immunol. 25 (2007), 171–192.
26. [26] Villadangos, J.A., Schnorrer, P., Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7:7 (2007), 543–555.
27. [27] Zhu, J., Paul, W.E., CD4 T cells: fates, functions, and faults. Blood 112:5 (2008), 1557–1569.
28. [28] Patil, N.K., Parajuli, N., MacMillan-Crow, L.A., Mayeux, P.R., Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. Am. J. Physiol. Renal Physiol. 306:7 (2014), F734–43.
29. [29] Abraham, E., Singer, M., Mechanisms of sepsis-induced organ dysfunction. Crit. Care Med. 35:10 (2007), 2408–2416.
30. [30] Holthoff, J.H., Wang, Z., Patil, N.K., Gokden, N., Mayeux, P.R., Rolipram improves renal perfusion and function during sepsis in the mouse. J. Pharmacol. Exp. Ther. 347:2 (2013), 357–364.
31. [31] Luyt, C.E., Kaiser, L., Virus detection in patients with severe pneumonia: still more questions than answers?. Am. J. Respir. Crit. Care Med. 186:4 (2012), 301–302.
32. [32] Walton, A.H., Muenzer, J.T., Rasche, D., Boomer, J.S., Sato, B., Brownstein, B.H., Pachot, A., Brooks, T.L., Deych, E., Shannon, W.D., Green, J.M., Storch, G.A., Hotchkiss, R.S., Reactivation of multiple viruses in patients with sepsis. PLoS One, 9(2), 2014, e98819.
33. [33] Kerr, J.F., Wyllie, A.H., Currie, A.R., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:4 (1972), 239–257.
34. [34] Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., Schmieg, R.E. Jr., Hui, J.J., Chang, K.C., Osborne, D.F., Freeman, B.D., Cobb, J.P., Buchman, T.G., Karl, I.E., Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166:11 (2001), 6952–6963.
35. [35] Norbury, C.J., Hickson, I.D., Cellular responses to DNA damage. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 367–401.
36. [36] Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35:4 (2007), 495–516.
37. [37] Strasser, A., Cory, S., Adams, J.M., Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30:18 (2011), 3667–3683.
38. [38] Wajant, H., The Fas signaling pathway: more than a paradigm. Science 296:5573 (2002), 1635–1636.
39. [39] Cory, S., Adams, J.M., The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:9 (2002), 647–656.
40. [40] Zha, J., Harada, H., Yang, E., Jockel, J., Korsmeyer, S.J., Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:4 (1996), 619–628.
41. [41] Yang, E., Zha, J., Jockel, J., Boise, L.H., Thompson, C.B., Korsmeyer, S.J., Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:2 (1995), 285–291.
42. [42] Newmeyer, D.D., Bossy-Wetzel, E., Kluck, R.M., Wolf, B.B., Beere, H.M., Green, D.R., Bcl-xL does not inhibit the function of Apaf-1. Cell Death Differ. 7:4 (2000), 402–407.
43. [43] Liu, F.T., Newland, A.C., Jia, L., Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem. Biophys. Res. Commun. 310:3 (2003), 956–962.
44. [44] Esposti, M.D., The roles of bid. Apoptosis 7:5 (2002), 433–440.
45. [45] Li, H., Zhu, H., Xu, C.J., Yuan, J., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:4 (1998), 491–501.
46. [46] Igney, F.H., Krammer, P.H., Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2:4 (2002), 277–288.
47. [47] Wang, S.D., Huang, K.J., Lin, Y.S., Lei, H.Y., Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 152:10 (1994), 5014–5021.
48. [48] Hotchkiss, R.S., Swanson, P.E., Cobb, J.P., Jacobson, A., Buchman, T.G., Karl, I.E., Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit. Care Med. 25:8 (1997), 1298–1307.
49. [49] Ayala, A., Herdon, C.D., Lehman, D.L., Ayala, C.A., Chaudry, I.H., Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 87:10 (1996), 4261–4275.
50. [50] Ayala, A., Herdon, C.D., Lehman, D.L., DeMaso, C.M., Ayala, C.A., Chaudry, I.H., The induction of accelerated thymic programmed cell death during polymicrobial sepsis: control by corticosteroids but not tumor necrosis factor. Shock 3:4 (1995), 259–267.
51. [51] Inoue, S., Unsinger, J., Davis, C.G., Muenzer, J.T., Ferguson, T.A., Chang, K., Osborne, D.F., Clark, A.T., Coopersmith, C.M., McDunn, J.E., Hotchkiss, R.S., IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 184:3 (2010), 1401–1409.
52. [52] Unsinger, J., McDonough, J.S., Shultz, L.D., Ferguson, T.A., Hotchkiss, R.S., Sepsis-induced human lymphocyte apoptosis and cytokine production in humanized mice. J. Leukoc. Biol. 86:2 (2009), 219–227.
53. [53] Patil, N.K., Luan, L., Bohannon, J.K., Guo, Y., Hernandez, A., Fensterheim, B., Sherwood, E.R., IL-15 superagonist expands mCD8+ T, NK and NKT cells after burn injury but fails to improve outcome during burn wound infection. PLoS One, 11(2), 2016, e0148452.
54. [54] Hotchkiss, R.S., Swanson, P.E., Knudson, C.M., Chang, K.C., Cobb, J.P., Osborne, D.F., Zollner, K.M., Buchman, T.G., Korsmeyer, S.J., Karl, I.E., Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol. 162:7 (1999), 4148–4156.
55. [55] Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., Chang, K.C., Cobb, J.P., Buchman, T.G., Korsmeyer, S.J., Karl, I.E., Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. U. S. A. 96:25 (1999), 14541–14546.
56. [56] Boomer, J.S., Shuherk-Shaffer, J., Hotchkiss, R.S., Green, J.M., A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit. Care, 16(3), 2012, R112.
57. [57] Hotchkiss, R.S., Osmon, S.B., Chang, K.C., Wagner, T.H., Coopersmith, C.M., Karl, I.E., Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174:8 (2005), 5110–5118.
58. [58] Weber, S.U., Schewe, J.C., Lehmann, L.E., Muller, S., Book, M., Klaschik, S., Hoeft, A., Stuber, F., Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit. Care, 12(5), 2008, R128.
59. [59] Chang, K.C., Unsinger, J., Davis, C.G., Schwulst, S.J., Muenzer, J.T., Strasser, A., Hotchkiss, R.S., Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J. 21:3 (2007), 708–719.
60. [60] Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15:8 (2015), 486–499.
61. [61] Zajac, A.J., Blattman, J.N., Murali-Krishna, K., Sourdive, D.J., Suresh, M., Altman, J.D., Ahmed, R., Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:12 (1998), 2205–2213.
62. [62] Acuto, O., Michel, F., CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3:12 (2003), 939–951.
63. [63] Schietinger, A., Greenberg, P.D., Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35:2 (2014), 51–60.
64. [64] Crawford, A., Wherry, E.J., The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr. Opin. Immunol. 21:2 (2009), 179–186.
65. [65] Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K.C., McDunn, J.E., Hotchkiss, R.S., Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 88:2 (2010), 233–240.
66. [66] Zhang, Y., Zhou, Y., Lou, J., Li, J., Bo, L., Zhu, K., Wan, X., Deng, X., Cai, Z., PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care, 14(6), 2010, R220.
67. [67] Huang, X., Venet, F., Wang, Y.L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.S., Ayala, A., PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci. U. S. A. 106:15 (2009), 6303–6308.
68. [68] Huang, X., Chen, Y., Chung, C.S., Yuan, Z., Monaghan, S.F., Wang, F., Ayala, A., Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J. Immunol. 192:3 (2014), 1091–1099.
69. [69] McNab, F.W., Berry, M.P., Graham, C.M., Bloch, S.A., Oni, T., Wilkinson, K.A., Wilkinson, R.J., Kon, O.M., Banchereau, J., Chaussabel, D., O'Garra, A., Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur. J. Immunol. 41:7 (2011), 1941–1947.
70. [70] Bowers, N.L., Helton, E.S., Huijbregts, R.P., Goepfert, P.A., Heath, S.L., Hel, Z., Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog., 10(3), 2014, e1003993.
71. [71] Guignant, C., Lepape, A., Huang, X., Kherouf, H., Denis, L., Poitevin, F., Malcus, C., Cheron, A., Allaouchiche, B., Gueyffier, F., Ayala, A., Monneret, G., Venet, F., Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care, 15(2), 2011, R99.
72. [72] Spec, A., Shindo, Y., Burnham, C.A., Wilson, S., Ablordeppey, E.A., Beiter, E.R., Chang, K., Drewry, A.M., Hotchkiss, R.S., T cells from patients with Candida sepsis display a suppressive immunophenotype. Crit. Care, 20, 2016, 15.
73. [73] Monneret, G., Venet, F., A rapidly progressing lymphocyte exhaustion after severe sepsis. Crit. Care, 16(4), 2012, 140.
74. [74] Shao, R., Fang, Y., Yu, H., Zhao, L., Jiang, Z., Li, C.S., Monocyte programmed death ligand-1 expression after 3–4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care, 20(1), 2016, 124.
75. [75] Zhang, Y., Li, J., Lou, J., Zhou, Y., Bo, L., Zhu, J., Zhu, K., Wan, X., Cai, Z., Deng, X., Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit. Care, 15(1), 2011, R70.
76. [76] Shubin, N.J., Monaghan, S.F., Heffernan, D.S., Chung, C.S., Ayala, A., B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Crit. Care, 17(6), 2013, R276.
77. [77] Bonten, M.J., Froon, A.H., Gaillard, C.A., Greve, J.W., de Leeuw, P.W., Drent, M., Stobberingh, E.E., Buurman, W.A., The systemic inflammatory response in the development of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:4 Pt 1 (1997), 1105–1113.
78. [78] Pelekanou, A., Tsangaris, I., Kotsaki, A., Karagianni, V., Giamarellou, H., Armaganidis, A., Giamarellos-Bourboulis, E.J., Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit. Care, 13(6), 2009, R172.
79. [79] van Dissel, J.T., van Langevelde, P., Westendorp, R.G., Kwappenberg, K., Frolich, M., Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351:9107 (1998), 950–953.
80. [80] Gogos, C.A., Drosou, E., Bassaris, H.P., Skoutelis, A., Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181:1 (2000), 176–180.
81. [81] de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C.G., de Vries, J.E., Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:5 (1991), 1209–1220.
82. [82] Ertel, W., Kremer, J.P., Kenney, J., Steckholzer, U., Jarrar, D., Trentz, O., Schildberg, F.W., Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:5 (1995), 1341–1347.
83. [83] Munoz, C., Carlet, J., Fitting, C., Misset, B., Bleriot, J.P., Cavaillon, J.M., Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88:5 (1991), 1747–1754.
84. [84] Rigato, O., Salomao, R., Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 19:2 (2003), 113–116.
85. [85] Venet, F., Chung, C.S., Kherouf, H., Geeraert, A., Malcus, C., Poitevin, F., Bohe, J., Lepape, A., Ayala, A., Monneret, G., Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (−)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35:4 (2009), 678–686.
86. [86] Josefowicz, S.Z., Lu, L.F., Rudensky, A.Y., Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
87. [87] Penaloza-MacMaster, P., Kamphorst, A.O., Wieland, A., Araki, K., Iyer, S.S., West, E.E., O'Mara, L., Yang, S., Konieczny, B.T., Sharpe, A.H., Freeman, G.J., Rudensky, A.Y., Ahmed, R., Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J. Exp. Med. 211:9 (2014), 1905–1918.
88. [88] Gilbert, K.M., Thoman, M., Bauche, K., Pham, T., Weigle, W.O., Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in naive T cells. Immunol. Invest. 26:4 (1997), 459–472.
89. [89] Wan, Y.Y., Flavell, R.A., TGF-beta and regulatory T cell in immunity and autoimmunity. J. Clin. Immunol. 28:6 (2008), 647–659.
90. [90] Knapp, S., Thalhammer, F., Locker, G.J., Laczika, K., Hollenstein, U., Frass, M., Winkler, S., Stoiser, B., Wilfing, A., Burgmann, H., Prognostic value of MIP-1 alpha, TGF-beta 2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis. Clin. Immunol. Immunopathol. 87:2 (1998), 139–144.
91. [91] Marie, C., Cavaillon, J.M., Losser, M.R., Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome. Ann. Intern. Med. 125:6 (1996), 520–521.
92. [92] Ayala, A., Knotts, J.B., Ertel, W., Perrin, M.M., Morrison, M.H., Chaudry, I.H., Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch. Surg. 128:1 (1993), 89–94 discussion 94-5.
93. [93] Ahmad, S., Choudhry, M.A., Shankar, R., Sayeed, M.M., Transforming growth factor-beta negatively modulates T-cell responses in sepsis. FEBS Lett. 402:2–3 (1997), 213–218.
94. [94] Roth, M.D., Golub, S.H., Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta 1 to suppress lymphocyte activation. J. Leukoc. Biol. 53:4 (1993), 366–371.
95. [95] Williams, M.A., Withington, S., Newland, A.C., Kelsey, S.M., Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J. Infect. Dis. 178:5 (1998), 1421–1433.
96. [96] Fan, X., Liu, Z., Jin, H., Yan, J., Liang, H.P., Alterations of dendritic cells in sepsis: featured role in immunoparalysis. BioMed Res. Int., 2015, 2015, 903720.
97. [97] Pradipta, I.S., Sodik, D.C., Lestari, K., Parwati, I., Halimah, E., Diantini, A., Abdulah, R., Antibiotic resistance in sepsis patients: evaluation and recommendation of antibiotic use. N. Am. J. Med. Sci. 5:6 (2013), 344–352.
98. [98] Williams, F.N., Herndon, D.N., Hawkins, H.K., Lee, J.O., Cox, R.A., Kulp, G.A., Finnerty, C.C., Chinkes, D.L., Jeschke, M.G., The leading causes of death after burn injury in a single pediatric burn center. Crit. Care, 13(6), 2009, R183.
99. [99] Namen, A.E., Lupton, S., Hjerrild, K., Wignall, J., Mochizuki, D.Y., Schmierer, A., Mosley, B., March, C.J., Urdal, D., Gillis, S., Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333:6173 (1988), 571–573.
100. [100] Rosenberg, S.A., Sportes, C., Ahmadzadeh, M., Fry, T.J., Ngo, L.T., Schwarz, S.L., Stetler-Stevenson, M., Morton, K.E., Mavroukakis, S.A., Morre, M., Buffet, R., Mackall, C.L., Gress, R.E., IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29:3 (2006), 313–319.
101. [101] Sportes, C., Hakim, F.T., Memon, S.A., Zhang, H., Chua, K.S., Brown, M.R., Fleisher, T.A., Krumlauf, M.C., Babb, R.R., Chow, C.K., Fry, T.J., Engels, J., Buffet, R., Morre, M., Amato, R.J., Venzon, D.J., Korngold, R., Pecora, A., Gress, R.E., Mackall, C.L., Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205:7 (2008), 1701–1714.
102. [102] Fry, T.J., Mackall, C.L., The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J. Immunol. 174:11 (2005), 6571–6576.
103. [103] Guimond, M., Veenstra, R.G., Grindler, D.J., Zhang, H., Cui, Y., Murphy, R.D., Kim, S.Y., Na, R., Hennighausen, L., Kurtulus, S., Erman, B., Matzinger, P., Merchant, M.S., Mackall, C.L., Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat. Immunol. 10:2 (2009), 149–157.
104. [104] Mackall, C.L., Fry, T.J., Gress, R.E., Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11:5 (2011), 330–342.
105. [105] Puel, A., Ziegler, S.F., Buckley, R.H., Leonard, W.J., Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20:4 (1998), 394–397.
106. [106] Cunningham-Rundles, C., Ponda, P.P., Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat. Rev. Immunol. 5:11 (2005), 880–892.
107. [107] Kasten, K.R., Prakash, P.S., Unsinger, J., Goetzman, H.S., England, L.G., Cave, C.M., Seitz, A.P., Mazuski, C.N., Zhou, T.T., Morre, M., Hotchkiss, R.S., Hildeman, D.A., Caldwell, C.C., Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78:11 (2010), 4714–4722.
108. [108] Venet, F., Foray, A.P., Villars-Mechin, A., Malcus, C., Poitevin-Later, F., Lepape, A., Monneret, G., IL-7 restores lymphocyte functions in septic patients. J. Immunol. 189:10 (2012), 5073–5081.
109. [109] Levy, Y., Sereti, I., Tambussi, G., Routy, J.P., Lelievre, J.D., Delfraissy, J.F., Molina, J.M., Fischl, M., Goujard, C., Rodriguez, B., Rouzioux, C., Avettand-Fenoel, V., Croughs, T., Beq, S., Morre, M., Poulin, J.F., Sekaly, R.P., Thiebaut, R., Lederman, M.M., Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin. Infect. Dis. 55:2 (2012), 291–300.
110. [110] Shindo, Y., Unsinger, J., Burnham, C.A., Green, J.M., Hotchkiss, R.S., Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 43:4 (2015), 334–343.
111. [111] Demaret, J., Dupont, G., Venet, F., Friggeri, A., Lepape, A., Rimmele, T., Morel, J., Monneret, G., STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin-7: a pilot study. J. Leukoc. Biol. 97:4 (2015), 791–796.
112. [112] Venet, F., Filipe-Santos, O., Lepape, A., Malcus, C., Poitevin-Later, F., Grives, A., Plantier, N., Pasqual, N., Monneret, G., Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit. Care Med. 41:1 (2013), 111–119.
113. [113] Perales, M.A., Goldberg, J.D., Yuan, J., Koehne, G., Lechner, L., Papadopoulos, E.B., Young, J.W., Jakubowski, A.A., Zaidi, B., Gallardo, H., Liu, C., Rasalan, T., Wolchok, J.D., Croughs, T., Morre, M., Devlin, S.M., van den Brink, M.R., Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 120:24 (2012), 4882–4891.
114. [114] Grabstein, K.H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M.A., Ahdieh, M., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:5161 (1994), 965–968.
115. [115] Doherty, T.M., Seder, R.A., Sher, A., Induction and regulation of IL-15 expression in murine macrophages. J. Immunol. 156:2 (1996), 735–741.
116. [116] Cui, G., Hara, T., Simmons, S., Wagatsuma, K., Abe, A., Miyachi, H., Kitano, S., Ishii, M., Tani-ichi, S., Ikuta, K., Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo. Proc. Natl. Acad. Sci. U. S. A. 111:5 (2014), 1915–1920.
117. [117] Khawam, K., Giron-Michel, J., Gu, Y., Perier, A., Giuliani, M., Caignard, A., Devocelle, A., Ferrini, S., Fabbi, M., Charpentier, B., Ludwig, A., Chouaib, S., Azzarone, B., Eid, P., Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res. 69:4 (2009), 1561–1569.
118. [118] Blaser, B.W., Schwind, N.R., Karol, S., Chang, D., Shin, S., Roychowdhury, S., Becknell, B., Ferketich, A.K., Kusewitt, D.F., Blazar, B.R., Caligiuri, M.A., Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood 108:7 (2006), 2463–2469.
119. [119] Castillo, E.F., Stonier, S.W., Frasca, L., Schluns, K.S., Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J. Immunol. 183:8 (2009), 4948–4956.
120. [120] Han, K.P., Zhu, X., Liu, B., Jeng, E., Kong, L., Yovandich, J.L., Vyas, V.V., Marcus, W.D., Chavaillaz, P.A., Romero, C.A., Rhode, P.R., Wong, H.C., IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56:3 (2011), 804–810.
121. [121] Steel, J.C., Waldmann, T.A., Morris, J.C., Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33:1 (2012), 35–41.
122. [122] Waldmann, T.A., Tagaya, Y., The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17 (1999), 19–49.
123. [123] Mueller, Y.M., Bojczuk, P.M., Halstead, E.S., Kim, A.H., Witek, J., Altman, J.D., Katsikis, P.D., IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101:3 (2003), 1024–1029.
124. [124] Sim, G.C., Radvanyi, L., The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 25:4 (2014), 377–390.
125. [125] Pelletier, M., Ratthe, C., Girard, D., Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases-1/2. FEBS Lett. 532:1–2 (2002), 164–170.
126. [126] Budagian, V., Bulanova, E., Paus, R., Bulfone-Paus, S., IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 17:4 (2006), 259–280.
127. [127] Anguille, S., Smits, E.L., Cools, N., Goossens, H., Berneman, Z.N., Van Tendeloo, V.F., Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J. Transl. Med., 7, 2009, 109.
128. [128] Kim, H.C., Cho, H.Y., Hah, Y.S., Role of IL-15 in sepsis-induced skeletal muscle atrophy and proteolysis. Tuberc. Respir.Dis. (Seoul) 73:6 (2012), 312–319.
129. [129] Guo, Y., Luan, L., Rabacal, W., Bohannon, J.K., Fensterheim, B.A., Hernandez, A., Sherwood, E.R., IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-gamma. J. Immunol. 195:5 (2015), 2353–2364.
130. [130] Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., Fleisher, T.A., Dubois, S.P., Perera, L.P., Stewart, D.M., Goldman, C.K., Bryant, B.R., Decker, J.M., Chen, J., Worthy, T.A., Figg, W.D. Sr., Peer, C.J., Sneller, M.C., Lane, H.C., Yovandich, J.L., Creekmore, S.P., Roederer, M., Waldmann, T.A., Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33:1 (2015), 74–82.
131. [131] Yu, P., Steel, J.C., Zhang, M., Morris, J.C., Waldmann, T.A., Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 16:24 (2010), 6019–6028.
132. [132] Chen, L., Han, X., Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125:9 (2015), 3384–3391.
133. [133] Chang, K.C., Burnham, C.A., Compton, S.M., Rasche, D.P., Mazuski, R.J., McDonough, J.S., Unsinger, J., Korman, A.J., Green, J.M., Hotchkiss, R.S., Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care, 17(3), 2013, R85.
134. [134] Shubin, N.J., Chung, C.S., Heffernan, D.S., Irwin, L.R., Monaghan, S.F., Ayala, A., BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J. Leukoc. Biol. 92:3 (2012), 593–603.
135. [135] Inoue, S., Bo, L., Bian, J., Unsinger, J., Chang, K., Hotchkiss, R.S., Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36:1 (2011), 38–44.
136. [136] Wang, L., Zhu, J., Shan, S., Qin, Y., Kong, Y., Liu, J., Wang, Y., Xie, Y., Repression of interferon-gamma expression in T cells by Prospero-related homeobox protein. Cell Res. 18:9 (2008), 911–920.
137. [137] Murphey, E.D., Lin, C.Y., McGuire, R.W., Toliver-Kinsky, T., Herndon, D.N., Sherwood, E.R., Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21:5 (2004), 415–425.
138. [138] Boehm, U., Klamp, T., Groot, M., Howard, J.C., Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997), 749–795.
139. [139] Davies, E.G., Isaacs, D., Levinsky, R.J., Defective immune interferon production and natural killer activity associated with poor neutrophil mobility and delayed umbilical cord separation. Clin. Exp. Immunol. 50:2 (1982), 454–460.
140. [140] Kox, W.J., Bone, R.C., Krausch, D., Docke, W.D., Kox, S.N., Wauer, H., Egerer, K., Querner, S., Asadullah, K., von Baehr, R., Volk, H.D., Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch. Intern. Med. 157:4 (1997), 389–393.
141. [141] Nalos, M., Santner-Nanan, B., Parnell, G., Tang, B., McLean, A.S., Nanan, R., Immune effects of interferon gamma in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185:1 (2012), 110–112.
142. [142] Dries, D.J., Jurkovich, G.J., Maier, R.V., Clemmer, T.P., Struve, S.N., Weigelt, J.A., Stanford, G.G., Herr, D.L., Champion, H.R., Lewis, F.R., et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch. Surg. 129:10 (1994), 1031–1041 discussion 1042.
143. [143] Wodnar-Filipowicz, A., Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol. Sci. 18 (2003), 247–251.
144. [144] Maraskovsky, E., Daro, E., Roux, E., Teepe, M., Maliszewski, C.R., Hoek, J., Caron, D., Lebsack, M.E., McKenna, H.J., In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:3 (2000), 878–884.
145. [145] Bohannon, J., Cui, W., Cox, R., Przkora, R., Sherwood, E., Toliver-Kinsky, T., Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. J. Immunol. 180:5 (2008), 3038–3048.
146. [146] Bohannon, J., Cui, W., Sherwood, E., Toliver-Kinsky, T., Dendritic cell modification of neutrophil responses to infection after burn injury. J. Immunol. 185:5 (2010), 2847–2853.
147. [147] Kapsenberg, M.L., Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3:12 (2003), 984–993.
148. [148] Pfister, O., Lorenz, V., Oikonomopoulos, A., Xu, L., Hauselmann, S.P., Mbah, C., Kaufmann, B.A., Liao, R., Wodnar-Filipowicz, A., Kuster, G.M., FLT3 activation improves post-myocardial infarction remodeling involving a cytoprotective effect on cardiomyocytes. J. Am. Coll. Cardiol. 63:10 (2014), 1011–1019.
149. [149] Marron, T.U., Binder, A., Bhardwaj, N., Kim-Schulze, S., Keler, T., Davis, T., Crowley, E., Salazar, A.M., Brody, J., In situ vaccine for low-grade lymphoma: combination of intratumoral Flt3L and poly-ICLC with low-dose radiotherapy (conference abstract). J. Clin. Oncol., 33(15), 2015, 174s.
150. [150] Jackson, H.J., Rafiq, S., Brentjens, R.J., Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13:6 (2016), 370–383.
151. [151] Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z., Liu, H., Grilley, B., Rooney, C.M., Heslop, H.E., Brenner, M.K., Dotti, G., CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121:5 (2011), 1822–1826.
152. [152] Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L., Grupp, S.A., Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371:16 (2014), 1507–1517.
153. [153] Maude, S.L., Shpall, E.J., Grupp, S.A., Chimeric antigen receptor T-cell therapy for ALL. Hematol. Am. Soc. Hematol. Educ. Program 2014:1 (2014), 559–564.
154. [154] Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M., Sadelain, M., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5(177), 2013, 177ra38.
155. [155] Kumaresan, P.R., Manuri, P.R., Albert, N.D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., Zhang, L., Najjar, A.M., Huls, M.H., Lee, D.A., Champlin, R.E., Kontoyiannis, D.P., Cooper, L.J., Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc. Natl. Acad. Sci. U. S. A. 111:29 (2014), 10660–10665.
156. [156] Dotti, G., Gottschalk, S., Savoldo, B., Brenner, M.K., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257:1 (2014), 107–126.
157. [157] Xiao, W., Mindrinos, M.N., Seok, J., Cuschieri, J., Cuenca, A.G., Gao, H., Hayden, D.L., Hennessy, L., Moore, E.E., Minei, J.P., Bankey, P.E., Johnson, J.L., Sperry, J., Nathens, A.B., Billiar, T.R., West, M.A., Brownstein, B.H., Mason, P.H., Baker, H.V., Finnerty, C.C., Jeschke, M.G., Lopez, M.C., Klein, M.B., Gamelli, R.L., Gibran, N.S., Arnoldo, B., Xu, W., Zhang, Y., Calvano, S.E., McDonald-Smith, G.P., Schoenfeld, D.A., Storey, J.D., Cobb, J.P., Warren, H.S., Moldawer, L.L., Herndon, D.N., Lowry, S.F., Maier, R.V., Davis, R.W., Tompkins, R.G., Inflammation and Host Response to Injury Large-Scale Collaborative Research Program, A genomic storm in critically injured humans. J. Exp. Med. 208:13 (2011), 2581–2590.
158. [158] Wong, H.R., Cvijanovich, N., Allen, G.L., Lin, R., Anas, N., Meyer, K., Freishtat, R.J., Monaco, M., Odoms, K., Sakthivel, B., Shanley, T.P., Genomics of Pediatric SIRS/Septic Shock Investigators, Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit. Care Med. 37:5 (2009), 1558–1566.
159. [159] Reinhart, K., Bauer, M., Riedemann, N.C., Hartog, C.S., New approaches to sepsis: molecular diagnostics and biomarkers. Clin. Microbiol. Rev. 25:4 (2012), 609–634.
160. [160] Drewry, A.M., Samra, N., Skrupky, L.P., Fuller, B.M., Compton, S.M., Hotchkiss, R.S., Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 42:5 (2014), 383–391.
161. [161] Docke, W.D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.D., Kox, W., Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:6 (1997), 678–681.
162. [162] Weaver, J.G., Rouse, M.S., Steckelberg, J.M., Badley, A.D., Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 18:11 (2004), 1185–1191.
163. [163] Bohannon, J.K., Luan, L., Hernandez, A., Afzal, A., Guo, Y., Patil, N.K., Fensterheim, B., Sherwood, E.R., Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury. J. Leukoc. Biol. 99:4 (2015), 629–640.
164. [164] Hernandez, A., Bohannon, J.K., Luan, L., Fensterheim, B.A., Guo, Y., Patil, N.K., McAdams, C., Wang, J., Sherwood, E.R., The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes. J. Leukoc. Biol., 2016, 10.1189/jlb.1A0216-072R.
165. [165] Romero, C.D., Varma, T.K., Hobbs, J.B., Reyes, A., Driver, B., Sherwood, E.R., The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect. Immun. 79:9 (2011), 3576–3587.
166. [166] Mata-Haro, V., Cekic, C., Martin, M., Chilton, P.M., Casella, C.R., Mitchell, T.C., The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:5831 (2007), 1628–1632.
167. [167] Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:2 (1999), 141–151.
168. [168] Okazaki, T., Honjo, T., PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19:7 (2007), 813–824.
169. [169] Patil, N.K., Bohannon, J.K., Luan, L., Guo, Y., Fensterheim, B., Hernandez, A., Wang, J., Sherwood, E.R., FLT3 ligand treatment attenuates T cell dysfunction and improves survival is a murine model of burn wound sepsis. Shock, 2016, 10.1097/shk.0000000000000688.